Igea discloses its 2021 Annual Report
Hoofddorp, the Netherlands, 20 October 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its 2021 Annual Report.
Convening Notice and Agenda
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites the shareholders to attend the annual general meeting on 1 December 2022 (the “AGM”), at the offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands. The meeting will start at 11:00 hours CET. Registration will start at 10:30 hours CET.
IGEA to get SIX approval to the semi-annual 2022 report disclosure
Hoofddorp, the Netherlands, 30 September 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the half year 2022 report.
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 09 August 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 15 July 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA Pharma has announced that LMH – an industrial holding company – has completed the due diligence process for a euro 6.000.000 committment to fund the swiss CBD extraction facility
Hoofddorp, the Netherlands, 13th July 2022. Today IGEA Pharma N.V. (SIX: IGPH) has announced that LMH Holding has completed the due diligence process on the Company in relation to its Euro 6.0 million commitment to fund the GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.
Notice to postpone annual general meeting IGEA Pharma N.V.
Dear Shareholder,
On 27 May 2022, the board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) invited you to (virtually) attend the annual general meeting on 30 June 2022 (the “AGM”), at offices of the Company at Siriusdreef 17, 2123 WT Hoofddorp, the Netherlands.
Note of the Board
The Board notices that the drafts of the Annual Report and the Annual Accounts for the financial year 2021 will unfortunately not be available in time for the upcoming AGM and therefore these documents as such cannot be approved and adopted, as the case may be, by the general meeting.